In vitro activities of vancomycin and teicoplanin against coagulase-negative staphylococci isolated from neutropenic patients.
This study reports the in vitro activities of vancomycin and teicoplanin against 185 coagulase-negative staphylococcal strains isolated from 80 neutropenic patients who received different antibiotic treatments. All strains were susceptible to vancomycin: MICs for 50 and 90% of strains tested were 2 and 4 mg/liter, respectively. Teicoplanin was less active, and MICs displayed a wider range. For only teicoplanin was there a correlation between resistance and previous treatment. At the 4- and 32-mg/liter breakpoint levels, only 20% of the strains isolated from patients without glycopeptide treatment were intermediate or resistant, whereas 49.2% of the strains from patients who had received vancomycin or teicoplanin or both were intermediate or resistant.
Maugein
J
J
Laboratoire de Bactériologie, Hôpital Haut-Lévêque, Pessac, France.
Pellegrin
J L
JL
Brossard
G
G
Fourche
J
J
Leng
B
B
Reiffers
J
J
D000380:Agranulocytosis / Q000382:microbiology*; D000970:Antineoplastic Agents / Q000009:adverse effects; D003030:Coagulase / Q000032:analysis*; D004352:Drug Resistance, Microbial; D006020:Glycopeptides / Q000494:pharmacology; D006801:Humans; D007938:Leukemia / Q000150:complications; D008826:Microbial Sensitivity Tests; D009503:Neutropenia / Q000139:chemically induced / Q000382:microbiology*; D013210:Staphylococcus / Q000187:drug effects* / Q000201:enzymology; D017334:Teicoplanin; D014640:Vancomycin / Q000494:pharmacology*
D000970:Antineoplastic Agents; D003030:Coagulase; D006020:Glycopeptides; D017334:Teicoplanin; D014640:Vancomycin